Barclays PLC Theravance Biopharma, Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

A detailed history of Barclays PLC transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Barclays PLC holds 65,580 shares of TBPH stock, worth $653,832. This represents 0.0% of its overall portfolio holdings.

Number of Shares
65,580
Previous 65,580 -0.0%
Holding current value
$653,832
Previous $529,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$7.66 - $10.25 $370,100 - $495,239
48,316 Added 279.87%
65,580 $529,000
Q2 2024

Aug 14, 2024
SELL
$8.29 - $9.92 $230,022 - $275,250
-27,747 Reduced 61.64%
17,264 $147,000
Q1 2024

May 15, 2024
SELL
$8.22 - $11.59 $306,984 - $432,840
-37,346 Reduced 45.35%
45,011 $404,000
Q4 2023

Feb 15, 2024
BUY
$8.58 - $11.4 $506,975 - $673,603
59,088 Added 253.93%
82,357 $925,000
Q3 2023

Nov 07, 2023
SELL
$8.38 - $10.44 $46,542 - $57,983
-5,554 Reduced 19.27%
23,269 $201,000
Q2 2023

Aug 03, 2023
SELL
$10.16 - $11.92 $79,034 - $92,725
-7,779 Reduced 21.25%
28,823 $298,000
Q1 2023

May 04, 2023
BUY
$9.87 - $11.44 $128,102 - $148,479
12,979 Added 54.94%
36,602 $397,000
Q4 2022

Feb 13, 2023
BUY
$9.65 - $11.34 $119,901 - $140,899
12,425 Added 110.96%
23,623 $265,000
Q3 2022

Nov 03, 2022
SELL
$8.39 - $10.22 $81,961 - $99,839
-9,769 Reduced 46.59%
11,198 $114,000
Q2 2022

Aug 12, 2022
SELL
$8.41 - $10.34 $64,395 - $79,173
-7,657 Reduced 26.75%
20,967 $190,000
Q1 2022

May 16, 2022
SELL
$8.33 - $12.96 $547,989 - $852,573
-65,785 Reduced 69.68%
28,624 $274,000
Q4 2021

Feb 14, 2022
BUY
$7.42 - $11.05 $264,292 - $393,589
35,619 Added 60.59%
94,409 $1.04 Million
Q3 2021

Nov 09, 2021
BUY
$6.77 - $14.41 $351,511 - $748,196
51,922 Added 756.0%
58,790 $435,000
Q2 2021

Aug 13, 2021
SELL
$14.52 - $22.46 $645,443 - $998,391
-44,452 Reduced 86.62%
6,868 $100,000
Q1 2021

May 13, 2021
BUY
$16.57 - $21.08 $417,829 - $531,553
25,216 Added 96.6%
51,320 $1.05 Million
Q4 2020

Feb 11, 2021
SELL
$14.89 - $20.16 $253,368 - $343,042
-17,016 Reduced 39.46%
26,104 $464,000
Q3 2020

Nov 12, 2020
SELL
$14.79 - $22.49 $415,953 - $632,508
-28,124 Reduced 39.48%
43,120 $637,000
Q2 2020

Aug 12, 2020
BUY
$20.64 - $30.69 $572,161 - $850,757
27,721 Added 63.69%
71,244 $1.5 Million
Q1 2020

May 13, 2020
SELL
$17.84 - $31.21 $199,540 - $349,083
-11,185 Reduced 20.44%
43,523 $1.01 Million
Q4 2019

Feb 10, 2020
BUY
$16.12 - $25.89 $155,203 - $249,268
9,628 Added 21.36%
54,708 $1.42 Million
Q3 2019

Nov 14, 2019
SELL
$16.51 - $23.78 $1.08 Million - $1.55 Million
-65,159 Reduced 59.11%
45,080 $879,000
Q2 2019

Aug 14, 2019
BUY
$15.6 - $25.15 $1.03 Million - $1.66 Million
66,146 Added 150.01%
110,239 $1.8 Million
Q1 2019

May 15, 2019
BUY
$22.57 - $28.15 $571,946 - $713,349
25,341 Added 135.14%
44,093 $1 Million
Q4 2018

Feb 14, 2019
SELL
$22.52 - $35.07 $286,769 - $446,581
-12,734 Reduced 40.44%
18,752 $481,000
Q3 2018

Nov 14, 2018
BUY
$22.83 - $32.67 $647,162 - $926,096
28,347 Added 903.06%
31,486 $1.03 Million
Q2 2018

Aug 14, 2018
SELL
$22.06 - $25.52 $191,613 - $221,666
-8,686 Reduced 73.45%
3,139 $72,000
Q1 2018

May 15, 2018
BUY
$23.37 - $29.71 $68,544 - $87,139
2,933 Added 32.98%
11,825 $286,000
Q4 2017

Feb 14, 2018
BUY
$25.82 - $35.66 $169,430 - $234,000
6,562 Added 281.63%
8,892 $248,000
Q3 2017

Nov 14, 2017
BUY
$23.88 - $34.96 $55,640 - $81,456
2,330
2,330 $79,000

Others Institutions Holding TBPH

# of Institutions
122
Shares Held
47.3M
Call Options Held
200
Put Options Held
12.8K
View Full List

About Theravance Biopharma, Inc.

TBPH Quotes by TradingView
  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $666M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email